Objective To characterise activation of the type I interferon (IFN) pathway in patients with
systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid …

Background Psoriasis is an immune-mediated disease characterized by aberrant epidermal
differentiation, surface scale formation, and marked cutaneous inflammation. To better …

Background & Aims MEDI2070 is a human monoclonal antibody that selectively inhibits
interleukin 23 (IL23), a cytokine implicated in the pathogenesis of Crohn's disease (CD). We …

Purpose: While immune checkpoint inhibitors such as anti–PD-L1 are rapidly becoming the
standard of care in the treatment of many cancers, only a subset of treated patients have …

Objective To assess the pharmacodynamic effects of sifalimumab, an investigational anti-
IFN-α monoclonal antibody, in the blood and muscle of adult dermatomyositis and …

Objective We investigated interferon‐stimulated gene 15 (ISG15), a poorly understood
ubiquitin‐like modifier, and its enzymatic pathway in dermatomyositis (DM), an autoimmune …

Small cell lung cancer (SCLC) is an aggressive disease with poor survival. A few
sequencing studies performed on limited number of samples have revealed potential …

Although cancer is largely seen as a disease stemming from genetic mutations, evidence
has implicated epigenetic regulation of gene expression as a driving force for tumorigenesis …

To identify potential pharmacodynamic biomarkers to guide dose selection in clinical trials
using anti-interferon-alpha (IFN-α) monoclonal antibody (mAb) therapy for systemic lupus …

Objective We investigated the mechanistic and pharmacological properties of anifrolumab, a
fully human, effector-null, anti-type I interferon (IFN) alpha receptor 1 (IFNAR1) monoclonal …